Review of Nexavar data presented at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO)

June 1 - 5, 2007
Chicago, Illinois

Results from various clinical studies including a pivotal Phase III trial in patients with advanced hepatocellular carcinoma, or primary liver cancer with Nexavar® (sorafenib) tablets were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO).


Monday, June 4, 2007 at 2:00 p.m. CEST:
Investor Conference Call - Review of Nexavar Data presented at ASCO

MP3 audio recording (presentation and discussion)

Fact Sheets
Nexavar Fact Sheet
Download (PDF, 87 KB) collect
Renal Cell Carcinoma Fact Sheet
Download (PDF, 52 KB) collect
Hepatocellular Carcinoma Fact Sheet
Download (PDF, 62 KB) collect
Melanoma Fact Sheet
Download (PDF, 55 KB) collect
Non-Small Cell Lung Cancer Fact Sheet
Download (PDF, 54 KB) collect



Abstract on Nexavar (Sorafenib) at ASCO 2007

Sorafenib improves survival in advanced Hepatocellular Carcinoma (HCC): Results of a Phase III randomized placebo-controlled trial (SHARP trial) - abstract LBA1

Clinical trials information: www.clinicaltrials.gov

American Cancer Society: www.cancer.org

American National Cancer Institute: www.cancer.gov

Information on kidney cancer: www.kidneycancer.org

Information on liver cancer: www.liverfoundation.org

Information on melanoma: www.melanomainternational.org

Information on lung cancer: www.lungcancer.org

Information on cancer incidence, prevalence and mortality (GLOBOCAN): www-dep.iarc.fr

Last updated: January 09, 2014 Copyright © Bayer AG